Nanoparticle-siRNA: A potential cancer therapy?

Critical Reviews in Oncology/Hematology

Volumn 98, Issue , 2016, Pages 159-169

  Young, Samuel Wang Sherng ^a   Stenzel, Martina ^b   Jia Lin, Yang ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer Therapy; Nano drugs; Nanoparticles; RNAi; SiRNA

Indexed keywords

MESSENGER RNA; NANOPARTICLE; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER THERAPY; DATA ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE SILENCING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; NANOANALYSIS; NONHUMAN; REVIEW; RNA INTERFERENCE; THERANOSTIC NANOMEDICINE; ANIMAL; CHEMISTRY; GENE THERAPY; GENE TRANSFER; GENETICS; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; NANOPARTICLES; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84957634220     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.10.015     Document Type: Review

References (99)

1. Adjei I., Sharma B., Labhasetwar V. Nanoparticles: cellular uptake and cytotoxicity. Nanomaterial 2014, 73-91. Springer, Netherlands. D.G. Capco, Y. Chen (Eds.).
2. Alhaddad A., et al. Nanodiamond as a vector for siRNA delivery to ewing sarcoma cells. Small 2011, 7(21):3087-3095.
3. An S., et al. Single-component self-assembled RNAi nanoparticles functionalized with tumor-targeting iNGR delivering abundant siRNA for efficient glioma therapy. Biomaterials 2015, 53(0):330-340.
4. Ardana A., et al. Polymeric siRNA delivery vectors: knocking down cancers with polymeric-based gene delivery systems. J. Chem. Technol. Biotechnol. 2015, 90(7):1196-1208.
5. Arvizo R.R., et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010, 10(7):2543-2548.
6. Bachelier R., et al. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. Int. J. Cancer 2014, 135(6):1319-1329.
7. Beddoes C.M., Case C.P., Briscoe W.H. Understanding nanoparticle cellular entry: a physicochemical perspective. Adv. Colloid Interface Sci. 2015, 218(0):48-68.
8. Bhatnagar I., Venkatesan J., Kim S.-K. Polymer functionalized single walled carbon nanotubes mediated drug delivery of gliotoxin in cancer cells. J. Biomed. Nanotechnol. 2014, 10(1):120-130.
9. Bhattacharyya S., et al. Inorganic nanoparticles in cancer therapy. Pharmaceutical Res. 2011, 28(2):237-259.
10. Bhujbal S.V., de Vos P., Niclou S.P. Drug and cell encapsulation: alternative delivery options for the treatment of malignant brain tumors. Adv. Drug Deliv. Rev. 2014, 67-68(0):142-153.
11. Braakhuis H.M., et al. Physicochemical characteristics of nanomaterials that affect pulmonary inflammation. Part. Fibre Toxicol. 2014, 11(18):1-25.
12. Cao Y. VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs. Nat. Rev. Endocrinol. 2014, 10(9):530-539.
13. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl. 3):4-10.
14. Castanotto D., Rossi J.J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009, 457(7228):426-433.
15. Chen Y., et al. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol. Ther. 2010, 18(9):1650-1656.
16. Chen C.-K., et al. Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells. Nanoscale 2014, 6(3):1567-1572.
17. Chen S.-H. Potential clinical applications of siRNA technique: benefits and limitations. Eur. J. Clin. Investig. 2011, 41(2):221-232.
18. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006, 6(4):662-668.
19. Commisso C., et al. Macr Opinocytosis of Protein is an Amino Acid Supply Route in Ras-transformed Cells 2013, Nature Advance Online Publication.
20. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148(2):135-146.
21. Davis M.E., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(7291):1067-1070.
22. Degueldre C., Favarger P.Y., Wold S. Gold colloid analysis by inductively coupled plasma-mass spectrometry in a single particle mode. Anal. Chim. Acta 2006, 555(2):263-268.
23. Deng Y., et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 2014, 538(2):217-227.
24. Desigaux L., et al. Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference. Proc. Natl. Acad. Sci. 2007, 104(42):16534-16539.
25. Dogini D.B., et al. The new world of RNAs. Genet. Mol. Biol. 2014, 37(Suppl. 1):285-293.
26. Eisenhauer E.A., et al. Phase I. Clinical trial design in cancer drug development. J. Clin. Oncol. 2000, 684.
27. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63(3):136-151.
28. Felice B., et al. Drug delivery vehicles on a nano-engineering perspective. Mater. Sci. Eng. C 2014, 41(0):178-195.
29. Feng Q., et al. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Biomaterials 2014, 35(18):5028-5038.
30. Gillespie David L., et al. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model. J. Neurosurg. 2015, 122(2):331-341.
31. Gomes-da-Silva L., Simões S., Moreira J. Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology. Cell. Mol. Life Sci. 2014, 71(8):1417-1438.
32. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J. Drug Target 2007, 15(7-8):457-464.
33. Gurunathan S., et al. Multidimensional effects of biologically synthesized silver nanoparticles in Helicobacter pylori, Helicobacter felis, and human lung (L132) and lung carcinoma A549 cells. Nanoscale Res. Lett. 2015, 10. p. 35.
34. Guzman-Villanueva D., et al. Formulation approaches to short interfering RNA and MicroRNA: challenges and implications. J. Pharm. Sci. 2012, 101(11):4046-4066.
35. Hennessy S. Postmarketing drug surveillance: an epidemiologic approach. Clin. Ther. 1998, 20(Suppl. 3 (0)):C32-C39.
36. Ho C.-C. The pH-controlled nanoparticles size of polydopamine for anti-cancer drug delivery. J. Mater. Sci. Mater. Med. 2013, 24(10):2381-2390.
37. Huang C., et al. Role of nanoparticle geometry in endocytosis: laying down to stand up. Nano Lett. 2013, 13(9):4546-4550.
38. Iyer A.K., et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 2006, 11(17-18):812-818.
39. Jeelani S., et al. The baffling human body and the boundless nanomaterial boon-a trap for cancer crab. J. Clin. Diagn. Res.: JCDR 2014, 8(7):ZE12.
40. Kanasty R., et al. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, 12(11):967-977.
41. Karnati H., et al. Therapeutic potential of siRNA and DNAzymes in cancer. Tumor Biol. 2014, 35(10):9505-9521.
42. Kaszuba M., et al. Measuring sub nanometre sizes using dynamic light scattering. J. Nanopart. Res. 2008, 10(5):823-829.
43. Katas H., Alpar H.O. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release 2006, 115(2):216-225.
44. Khawar I.A., Kim J.H., Kuh H.-J. Improving drug delivery to solid tumors: Priming the tumor microenvironment. J. Control. Release 2015, 201(0):78-89.
45. Kim T. Applications of inorganic nanoparticles as therapeutic agents. Nanotechnology 2014, 25(1):012001.
46. Kraft J.C., et al. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J. Pharm. Sci. 2014, 103(1):29-52.
47. Landen C.N., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering rna delivery. Cancer Res. 2005, 65(15):6910-6918.
48. Lee J.-M., Yoon T.-J., Cho Y.-S. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. BioMed. Res. Int. 2013, p. 10.
49. Li F., et al. Thermal stability of DNA functionalized gold nanoparticles. Bioconjug. Chem. 2013, 24(11):1790-1797.
50. Li T., et al. Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs. Nucleic Acid Ther. 2014, 24(4):302-312.
51. Li X. Size and shape effects on receptor-mediated endocytosis of nanoparticles. J. Appl. Phys. 2012, 111(2):024702.
52. 2 nanoparticles in the preconcentration of trace chromium and lead from sample solution and determination by inductively coupled plasma atomic emission spectrometry. Microchim. Acta 2005, 151(1-2):81-88.
53. Lin T.-y., Rodriguez C.O., Li Y. Nanomedicine in veterinary oncology. Vet. J. 2015, 0.
54. Liu Y., et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale 2014, 6(6):3231-3242.
55. Longmire M., Choyke P.L., Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 2008, 3(5):703-717.
56. Lu Q., et al. RNA polymer translocation with single-walled carbon nanotubes. Nano Lett. 2004, 4(12):2473-2477.
57. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 2009, 71(3):409-419.
58. Matsumura Y. The drug discovery by nanomedicine and its clinical experience. Jpn. J. Clin. Oncol. 2014, 44(6):515-525.
59. Medarova Z., et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 2007, 13(3):372-377.
60. Mody V.V., et al. Magnetic nanoparticle drug delivery systems for targeting tumor. Appl. Nanosci. 2014, 4(4):385-392.
61. Murata N., et al. Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release 2008, 126(3):246-254.
62. Murgo A.J., et al. Designing phase 0 cancer clinical trials. Clin. Cancer Res. 2008, 14(12):3675-3682.
63. Murugan K., et al. Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures. Int. J. Nanomed. 2015, 10:2191-2206.
64. Muthu M.S., et al. Nanotheranostics-application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014, 4(6):660-677.
65. Nam H.Y., et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J. Control. Release 2009, 135(3):259-267.
66. Niepel M., et al. Analysis of growth factor signaling in genetically diverse breast cancer lines. BMC Biol. 2014, 12:20.
67. Oh Y.-K., Park T.G. siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 2009, 61(10):850-862.
68. Oh N., Park J.-H. Endocytosis and exocytosis of nanoparticles in mammalian cells. Int. J. Nanomed. 2014, 9(Suppl. 1):51-63.
69. Pai S.I., et al. Prospects of RNA interference therapy for cancer. Gene Ther. 2005, 13(6):464-477.
70. Pal S., Tak Y.K., Song J.M. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the gram-negative bacterium E. coli. Appl. Environ. Microbiol. 2007, 73(6):1712-1720.
71. Patil V.S., Zhou R., Rana T.M. Gene regulation by non-coding RNAs. Crit. Rev. Biochem. Mol. Biol. 2014, 49(1):16-32.
72. Prabha S., et al. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int. J. Pharm. 2002, 244(1-2):105-115.
73. Reischl D., Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine 2009, 5(1):8-20.
74. Resnier P., et al. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials 2013, 34(27):6429-6443.
75. Roberts W.G., et al. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am. J. Pathol. 1998, 153(4):1239-1248.
76. Rubinstein L.V., et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J. Clin. Oncol. 2005, 23(28):7199-7206.
77. Ryu J.H., et al. Theranostic nanoparticles for future personalized medicine. J. Control. Release 2014, 190:477-484.
78. Sailor M.J., Park J.H. Hybrid nanoparticles for detection and treatment of cancer. Adv. Mater. 2012, 24(28):3779-3802.
79. Scheicher B., Schachner-Nedherer A.L., Zimmer A. Protamine-oligonucleotide-nanoparticles: recent advances in drug delivery and drug targeting. Eur. J. Pharm. Sci. 2015, 0.
80. Sen G.L., Blau H.M. A brief history of RNAi: the silence of the genes. FASEB J. 2006, 20(9):1293-1299.
81. Shim J.-H., Lee B.-J., Cho Y.W. Thermal stability of unsupported gold nanoparticle: a molecular dynamics study. Surf. Sci. 2002, 512(3):262-268.
82. Simasi J., et al. The role of BIM-EL and BCL2-α on the efficacy of erlotinib and gefitinib in lung cancer. Respir. Physiol. Neurobiol. 2015, 209(0):64-68.
83. Singha K., Namgung R., Kim W.J. Polymers in small-interfering RNA delivery. Nucleic Ther. 2011, 21(3):133-147.
84. Sonnad S.S., et al. Recommendations for the design of Phase 3 pharmaceutical trials that are more informative for patients, clinicians, and payers. Contemp. Clin. Trials 2013, 36(2):356-361.
85. Tabernero J., et al. First-in-humans trial of an rna interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3(4):406-417.
86. Tan W.B., Jiang S., Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007, 28(8):1565-1571.
87. Tomalia D. In quest of a systematic framework for unifying and defining nanoscience. J. Nanopart. Res. 2009, 11(6):1251-1310.
88. Toy R., et al. Shaping cancer nanomedicine: The effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (London, England) 2014, 9(1):121-134.
89. U.S. National Institutes of Health. TKM 080301 for Primary or Secondary Liver Cancer. 2014 [cited 2014 18 March]; Available from:. http://www.clinicaltrials.gov/ct2/show/NCT01437007%3Fterm=siRNA+cancer&rank=6.
90. Uchino K., Ochiya T., Takeshita F. RNAi therapeutics and applications of MicroRNAs in cancer treatment. Jpn. J. Clin. Oncol. 2013, 43(6):596-607.
91. Wang J., et al. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010, 12(4):492-503.
92. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8(2):129-138.
93. Wu M., et al. The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J. Theor. Biol. 2013, 320(0):131-151.
94. Yin H., et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15(8):541-555.
95. Zhang H., et al. Molecular dynamics simulations, thermodynamic analysis, and experimental study of phase stability of zinc sulfide nanoparticles. J. Phys. Chem. B 2003, 107(47):13051-13060.
96. Zhang L., Li Y., Jimmy C.Y. Chemical modification of inorganic nanostructures for targeted and controlled drug delivery in cancer treatment. J. Mater. Chem. B 2014, 2(5):452-470.
97. Zhang J., Li X., Huang L. Non-viral nanocarriers for siRNA delivery in breast cancer. J. Control. Release 2014, 190(0):440-450.
98. Zins K., et al. Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy. RNA Interference 2015, 143-161. Springer, New York. M. Sioud (Ed.).
99. Zuckerman J.E., et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(31):11449-11454.